Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.55 |
| ▸ | AGXT | P21549 | 2/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.51 |
| ▸ | CMA1 | P23946 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | LPO | P22079 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10549588 | 0.88 | SMN1; SMN2 (0.56) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL5703462 | 0.81 | TAAR1 (0.61) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL362937 | 0.81 | TAAR1 (0.59) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL5957775 | 0.81 | TAAR1 (0.55) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL11503299 | 0.81 | TAAR1 (0.55) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL101334 | 0.81 | TAAR1 (0.55) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL12484975 | 0.79 | ALDH1A1 (0.50) | MAOB | |
| SCHEMBL9292349 | 0.79 | TSHR (0.47) | MAOB | |
| SCHEMBL8354908 | 0.79 | CHRM2 (0.62) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL28696933 | 0.79 | CHRM2 (0.62) | IDO1AGXTCHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112876507-B | Trisubstituted olefin tertiary phosphine compound and preparation method thereof | 湖北大学 | 2022-08-30 | — | — | CN | disclosed |
| CN-112876507-A | Trisubstituted olefin tertiary phosphine compound and preparation method thereof | 湖北大学 | 2021-06-01 | — | — | CN | disclosed |
| US-20210047457-A1 | COMPOUND, RESIN, COMPOSITION AND PATTERN FORMATION METHOD | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2021-02-18 | — | — | US | disclosed |
| EP-1740551-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20050143597-A1 | Process for producing carbonyl compound | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2005-06-30 | — | — | US | disclosed |
| US-6121459-A | Single pot process for producing (Z)-azabicyclo oxime ethers | WARNER-LAMBERT COMPANY (US) | 2000-09-19 | — | — | US | disclosed |
| EP-1021446-A1 | SINGLE POT PROCESS FOR PRODUCING (Z)-AZABICYCLO OXIME ETHERS | WARNER-LAMBERT COMPANY (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1998032758-A1 | SINGLE POT PROCESS FOR PRODUCING (Z)-AZABICYCLO OXIME ETHERS | WARNER-LAMBERT COMPANY (US) | 1998-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143597-A1 | Process for producing carbonyl compound | MCCC2, CBR3, COASY | TAAR1 3593/4885IDO1 1681/4885AGXT 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.